Endometriosis and Inflammation: Why Immune Dysfunction Is Central to This Condition

Endometriosis is defined by the presence of endometrial-like tissue outside the uterus, most commonly on the pelvic peritoneum, ovaries, and fallopian tubes, though it can affect the bowel, bladder, diaphragm, and in rare cases, distant organs. It affects approximately 190 million women worldwide, or roughly 10 percent of those of reproductive age. Despite this prevalence, the average time from symptom onset to diagnosis remains 7 to 10 years, reflecting both the nonspecific nature of its symptoms, primarily pelvic pain and infertility, and a historical tendency to normalize women's pain.

The pathophysiology of endometriosis centers on two simultaneous failures: the inability of the peritoneal immune environment to clear ectopic endometrial cells, and the active promotion of their survival and growth by a chronically inflamed peritoneal milieu. Endometriosis is, in a fundamental sense, a disease of immune dysfunction that expresses itself through reproductive tissue.

Retrograde Menstruation and Immune Failure

The most widely accepted mechanistic model for endometriosis begins with retrograde menstruation, the backflow of menstrual blood and endometrial cells through the fallopian tubes into the peritoneal cavity. Retrograde menstruation occurs in 70 to 90 percent of women, yet only about 10 percent develop endometriosis. This discrepancy points to an immune failure in women who develop the condition: their peritoneal immune environment, primarily natural killer cells and macrophages, fails to clear the ectopic endometrial cells before they implant and establish blood supplies.

In women with endometriosis, peritoneal natural killer (pNK) cell cytotoxicity against endometrial cells is significantly reduced compared to healthy women, allowing ectopic cells to evade immune clearance. Peritoneal macrophages in endometriosis adopt an M2 pro-survival phenotype that promotes angiogenesis and tissue remodeling supporting lesion growth, rather than the M1 cytotoxic phenotype that would eliminate ectopic cells. These immune abnormalities are present not only in the peritoneal cavity but in peripheral blood, indicating that endometriosis involves systemic immune dysregulation rather than merely a local peritoneal defect.

The Inflammatory Peritoneal Environment

Once ectopic endometrial cells establish themselves, they create a highly inflammatory peritoneal microenvironment that promotes their own survival and growth. Endometriotic lesions produce prostaglandin E2 (PGE2), which promotes local angiogenesis, suppresses NK cell activity, and sensitizes pain receptors. They secrete IL-6, IL-8, TNF-alpha, VEGF, and MCP-1 into peritoneal fluid, recruiting additional inflammatory cells and promoting the vascularization that makes lesions self-sustaining. Peritoneal fluid from women with endometriosis is measurably more inflammatory than that from healthy women, containing 3 to 10 times higher concentrations of pro-inflammatory cytokines.

The inflammation also drives the neuroangiogenesis, growth of new nerve fibers into lesions, that is responsible for the severe chronic pelvic pain characteristic of the condition. IL-1 beta and TNF-alpha stimulate the outgrowth of sensory nerve fibers into endometriotic implants, creating a direct neural connection between the lesions and the pain-processing nervous system. This explains why endometriosis pain is often disproportionate to lesion size or number: the quality of neural innervation and central sensitization, both inflammation-dependent processes, determine pain severity more than lesion burden alone.

Systemic Inflammation and Whole-Body Effects

Endometriosis is not confined to the pelvis in its inflammatory consequences. Systemic CRP, IL-6, and TNF-alpha are elevated in women with endometriosis compared to controls, and the degree of systemic inflammation correlates with disease stage and symptom severity in several studies. Women with endometriosis have significantly higher rates of autoimmune conditions including thyroid disease, lupus, and inflammatory bowel disease compared to the general population, consistent with a systemic immune dysregulation that extends beyond pelvic immune function.

Emerging research has linked endometriosis to elevated cardiovascular risk and accelerated biological aging, both plausibly attributable to the chronic systemic inflammatory burden the condition creates. The gut microbiome is also consistently altered in endometriosis, with reduced diversity and specific compositional changes that correlate with symptom severity. Whether gut dysbiosis contributes to endometriosis development or results from the condition's effects on gut function and immune regulation is an active area of investigation, with preliminary data suggesting that gut-targeted interventions may influence disease activity through modulation of estrogen metabolism and systemic inflammatory tone.

Anti-Inflammatory Strategies in Endometriosis

Conventional endometriosis management focuses on hormonal suppression of the menstrual cycle (using combined oral contraceptives, GnRH agonists, or progestins) and surgical excision of lesions. While these approaches reduce pain for many women, they do not address the underlying immune dysfunction, and recurrence rates following surgery are high. Anti-inflammatory complementary approaches are increasingly studied as adjuncts to conventional treatment.

Omega-3 fatty acid supplementation has shown meaningful reductions in dysmenorrhea and pelvic pain in multiple controlled trials, likely through prostaglandin E2 suppression and resolution-promoting mediator production. A Mediterranean-style diet, which reduces the omega-6 to omega-3 ratio and provides abundant polyphenols, is associated with reduced endometriosis risk and lower symptom scores in observational data. Curcumin inhibits PGE2 production, reduces VEGF-mediated angiogenesis, and has shown anti-proliferative effects on endometriotic cells in pre-clinical models. Gut microbiome optimization through fiber-rich diets and targeted probiotics is an emerging strategy given the consistent microbiome dysbiosis findings. While none of these interventions replaces medical management, they address inflammatory dimensions of the condition that conventional treatments do not.